When symptoms such as low energy, poor sleep, mood changes, low libido, or persistent weight gain are present, evaluating hormone health may provide additional insight into factors affecting weight management
Notably, retatrutide trials showed an overwhelming clearance of liver fat, with some cohorts experiencing up to an 80% reduction in hepatic lipid content, presenting a massive benefit for individuals dealing with metabolic dysfunction-associated steatotic liver disease (MASLD)
65 years), baseline eGFR ( 40%), treatment with 10 mg empagliflozin for a median time of 26.2 months reduced the risk of a composite of CV death or hospitalization for HF by 21%, and effect which was mainly related to a 29% lower risk of hospitalization for HF
To schedule a medical weight loss consultation with Atrium Medical, call 212-457-1722 or book online